Recent Quotes (30 days)

You have no recent quotes
chg | %

Arbutus Biopharma Corp  

(Public, TSE:TKM)   Watch this stock  
Find more results for TKM
Delayed:   3:59PM EST
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 9.55 - 34.66
Open     -
Vol / Avg. 0.00/31,124.00
Mkt cap 502.11M
P/E     -
Div/yield     -
EPS -2.15
Shares 22.31M
Beta -0.58
Inst. own     -
Aug 2, 2017
Q2 2017 Arbutus Biopharma Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 20, 2017
Arbutus Biopharma Corp at JMP Securities Life Science Conference
Jun 6, 2017
Arbutus Biopharma Corp at Jefferies Healthcare Conference
May 24, 2017
Arbutus Biopharma Corp Annual Shareholders Meeting
May 4, 2017
Q1 2017 Arbutus Biopharma Corp Earnings Call - Webcast
May 4, 2017
Q1 2017 Arbutus Biopharma Corp Earnings Release
May 2, 2017
Arbutus Biopharma Corp at Bloom Burton & Co. Healthcare Investor Conference

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -197.25% -90.95%
Operating margin -156.90% -78.59%
EBITD margin - -74.63%
Return on average assets -26.84% -22.63%
Return on average equity -34.40% -28.10%
Employees 85 -
CDP Score - -


100-8900 Glenlyon Pky
+1-604-4193200 (Phone)
+1-604-4193201 (Fax)

Website links


Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company's lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.